Anticancer Fund

At the Anticancer Fund, every day starts with a clear purpose: to extend lives and improve the quality of life for cancer patients. We are driven by results that matter—treatments that work, knowledge that empowers, and research that makes a difference. We don’t settle for what's convenient or mainstream. Instead, we take on challenges others avoid. We fund neglected but valuable research, giving it the opportunity to deliver real progress. 🔬 And we provide patients and their loved ones with answers that are built on science—reliable and transparant. 📝 In 2024, we took bold strides forward. A new clinical trial was launched for children and young adults with gliomas, bringing the total number of trials we are recruiting patients for to seven. 👨🔬 Three more trials are in preparation, ready to begin soon, promising new treatments for patients. Meanwhile, our free information service, My Cancer Navigator 🧭, helped nearly 400 people—providing clear, science-based answers to patients every single day. This commitment demands focus, effort, and collaboration. It wouldn’t be possible without your support. 👏 You enable us to challenge the status quo and push boundaries, ensuring that the work we do creates meaningful outcomes for those who need it most. As we enter 2025, let’s stay grounded in action and driven by results. Thank you for walking alongside us. Together, we can improve lives—not someday, but today. 🔥 Warm wishes for 2025. 💚 💙 The Anticancer Fund-team #anticancerfund #antikankerfonds #fondsanticancer #mycancernavigator

📣 Pleased to share an upcoming event, organised by REMEDi4ALL . We have been part of this initiative since the very beginning and are proud it became Europe's main community for medicines repurposing. Together with 24 organisations 🤝, we have been working on numerous projects to drive forward the repurposing of drugs and the #iDR25 gathering in Amsterdam is a perfect time to share this expertise.  💡So come and join us, early bird registrations are open. ✅ Exchange knowledge with leaders driving innovation in drug repurposing ✅ Discover new opportunities to expand your reach and impact ✅ Showcase your expertise to peers and potential collaborators ✅ Build lasting partnerships with a diverse, multidisciplinary audience More information and registration here: https://lnkd.in/eb32WZd5 #anticancerfund #drugrepurposing #cancerresearch

Zo dankbaar voor deze oprechte getuigenis van Martijn Bomas. Hij contacteerde onze My Cancer Navigator met vragen over zijn behandeling. Blij dat we hebben kunnen helpen. 💚 💙 #anticancerfund #antikankerfonds #mycancernavigator

New Medicines Recommended by CHMP in 2024 The Committee for Medicinal Products for Human Use (CHMP) recommended 💊 114 new medicines for human use in 2024, of which 48 contain a completely new active substance and 16 are for the treatment of rare diseases. It is the first time since 2009 more than 100 positive opinions are granted! ✨ Wrap-up for 2024: ✅ 114 medicines obtained a positive opinion ⛔ 5 medicines got a negative opinion ☑️ 88 medicines received a positive opinion on extension of therapeutic indications 🚫 8 medicines withdrew their applications  In #oncology:  🔹 New medicines: 17 🔹 Biosimilars and generics: 16 🔹 Extension of therapeutic indications: 35 Compiled by Michael Maris, PhD, MBA

📊 CHMP 2024 Wrap-Up: Key Highlights The Committee for Medicinal Products for Human Use (CHMP) had an impactful year in advancing medicines: ✅ 114 medicines obtained a positive opinion ❌ 5 medicines received a negative opinion 🔄 88 medicines were granted a positive opinion for the extension of therapeutic indications 🚫 8 medicines withdrew their applications These numbers reflect significant progress in bringing treatments to patients while ensuring rigorous evaluation. The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines. It plays a vital role in the authorisation of medicines in the European Union. The committee meets once a month. Compiled by Michael Maris, PhD, MBA #anticancerfund #antikankerfonds #fondsanticancer

Proud to be part of this new consortium. 👨🔬 🔬 Joining forces is most important to tackle cancer. Together we can do so much more! 🤝 #anticancerfund #cancerresearch #FORCEconsortium

New Medicines Recommended by CHMP The Committee for Medicinal Products for Human Use (CHMP) met between 9th and 12th of December and recommended 17 new medicines for approval. Additionally, 8 medicines received extensions of their therapeutic indications, with 3 and 2 in the oncology field, respectively. 🆕 New medicines recommended for approval: 💊 Imetelstat (Rytelo®), an oligonucleotide telomerase inhibitor causing telomere shortening, is now indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low or intermediate risk myelodysplastic syndromes (MDS) without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. 💊 Belzutifan (Welireg®), small molecule inhibitor of HIF-2α is now indicated 1) for the treatment of adult patients with advanced clear cell renal cell carcinoma that progressed following two or more lines of therapy that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies and 2) for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma, central nervous system haemangioblastomas, or pancreatic neuroendocrine tumours, and for whom localised procedures are unsuitable. 🆕 New Biosimilar recommended for Approval: 💊 Denosumab (Osenvelt®), a human monoclonal IgG2 antibody that targets the protein RANKL, is now indicated for 1) the prevention of skeletal related events in adults with advanced malignancies involving bone and 2) the treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. 📈 Recommendations on extensions of therapeutic indication: The following indications were added to the current indications: 🔄 Blinatumomab (Blincyto®) is now also indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precursor ALL. 🔄 Dostarlimab (Jemperli®) is now also indicated 1) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy and 2) as monotherapy for the treatment of adult patients with dMMR)/MSI‑H recurrent or advanced EC that has progressed on or following prior treatment with a platinum‑containing regimen. 🔔 Note: All these positive opinions are still awaiting EC decision before an official marketing authorization for the EU can be granted. Compiled by Michael Maris, PhD, MBA #anticancerfund #antikankerfonds #fondsanticancer Lindis Biotech GmbH Novartis BeiGene

📣 Pleased to share an upcoming event, organised by REMEDi4ALL . We have been part of this initiative since the very beginning and are proud it became Europe's main community for medicines repurposing. Together with 24 organisations 🤝, we have been working on numerous projects to drive forward the repurposing of drugs and the #iDR25 gathering in Amsterdam is a perfect time to share this expertise.  💡So come and join us, early bird registrations are open. ✅ Exchange knowledge with leaders driving innovation in drug repurposing ✅ Discover new opportunities to expand your reach and impact ✅ Showcase your expertise to peers and potential collaborators ✅ Build lasting partnerships with a diverse, multidisciplinary audience More information and registration here: https://lnkd.in/eb32WZd5 #anticancerfund #drugrepurposing #cancerresearch

Check out what attendees from last year said about the inaugural International #DrugRepurposing Conference. Join us at #iDR25 on 7-8 May 2025 in Amsterdam to join the discussions that will shape the future of medicines repurposing. ➡️ The early bird tickets are still available. Check it out here: https://lnkd.in/eb32WZd5